REAL-WORLD MANAGEMENT OF ORAL FACTOR XA INHIBITOR BLEEDING-RELATED HOSPITALIZATIONS WITH ANDEXANET ALFA OR 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE

Craig I. Coleman,Sherry Danese,Julie Ulloa, Grace Xiao,Belinda Lovelace

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2020）

引用 5|浏览22

暂无评分

摘要

Prior to US approval of andexanet, clinicians often relied on off label use of 4 factor prothrombin complex concentrate (4FPCC) to manage oral factor Xa inhibitor (oFXaI) associated bleeding related hospitalizations. We describe utilization and outcomes associated with andexanet and 4FPCC for

查看译文

关键词

Bleeding Risk

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要